Issels® Immunotherapy for Cancer is non-toxic and was developed in Germany in 1951 by Josef M. Issels at the worldwide first hospital for Immunotherapy for Cancer. In view of the impressive success rate with standard therapy-resistant cancers, all German insurance companies covered the whole treatment in his 120 bed cancer hospital. Dr. Issels was invited to become an expert member of the official German Government Commission in the Fight against Cancer.
Today this treatment is unique and only administered by Issels Doctors, at the Issels® Immunotherapy Centers, who have the experience to integrate the non-toxic vaccines in the right dosage and intervals into the comprehensive non-toxic Immunotherapy core treatment program.
Issels® Immunotherapy is individualized and has no adverse side-effects. This is in contrast to the pharmaceutically produced drugs called immunotherapy that are currently used in oncology, which have shown serious life-threatening reactions in a variety of patients.
The Issels cancer vaccine and cell therapies are cultured from the patient’s own immune cells, in the presence of the patient’s own tumor antigens. They are highly individualized, specific, and non-toxic, yet powerful.
Issels® Immunotherapy integrates the vaccine and cell therapies which activate the cellular immunity, into the comprehensive treatment program in order to also activate the various other levels of the body’s very complex defense mechanisms.
Issels® Immunotherapy for Cancer is not limited to one single modality such as a vaccine, or a drug or another monotherapy. It integrates treatment components that complement and enhance one another.
Issels® Immunotherapy for Cancer is not a trial. It is a comprehensive treatment program with a history of complete long-term remission of a variety of stage IV standard treatment-resistant cancers.
Our present Issels doctors’ expertise and many years of clinical experience with the successful administration of our personalized and non-toxic Immunotherapy for Cancer, either on its own or in combination with targeted cancer treatment at our US Treatment Center play a decisive role in the treatment outcomes.